Why MannKind Corporation (MNKD) Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biopharmaceutical company¬†MannKind Corporation (NASDAQ:MNKD) has received a distressing two-star ranking.

MannKind Corporation (NASDAQ:MNKD)

With that in mind, let’s take a closer look at MannKind Corporation (NASDAQ:MNKD) and see what CAPS investors are saying about the stock right now.


Headquarters (founded)

Valencia, Calif. (1991)

Market Cap

$2.1 billion



Trailing-12-Month Revenue

$35 thousand


Founder/Chairman/CEO Alfred Mann

President/COO Hakan Edstrom

Return on Equity (average, past 3 years)



$28.0 million / $332.0 million


Eli Lilly (NYSE:LLY)
GlaxoSmithKline (NYSE:GSK)
Novo (NYSE:NVO) Nordisk

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 16% of the 695 members who have rated MannKind Corporation (NASDAQ:MNKD) believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped the stock’s recent surge as particularly unsustainable:

At the end of last year I looked over all the stocks in my biopharma database and tried to predict which would be the biggest runner of 2013. My conclusion? MannKind Corporation (NASDAQ:MNKD). But I never bought in or even green thumbed because the run started earlier than I expected and I kept waiting for a pullback that never came. … And after the company solidified their guidance to topline results of Affinity 1 and Affinity 2 in mid August, the stock went parabolic. The moral: don’t be so obsessed with catching a stock at the absolute bottom. …

Now I’m left with another crummy red thumb. I don’t think MannKind Corporation (NASDAQ:MNKD) is worth two billion even if the Affinity trials are a resounding success and Afrezza is approved the next time round. I’ve been a long-term bear on MannKind for years and my reasons are well-documented here. A 300% rise in share price this year is completely unjustified and simply represents traders playing the “greater fool” game. I’m terrible at judging when that game will end but at some inflection point, whether it is positive data or drug approval, this stub is going to tank.

The article Why MannKind Is Poised to Pull Back originally appeared on Fool.com and is written by Brian Pacampara.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 Р2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!